Antibiotic Treatment for Enterococcus faecalis Infections
For vancomycin-susceptible E. faecalis infections, ampicillin (or amoxicillin) is the first-line treatment, with linezolid as the primary alternative for serious infections. 1
Treatment Algorithm Based on Infection Type and Resistance Pattern
For Vancomycin-Susceptible E. faecalis
Serious/Invasive Infections (Bacteremia, Endocarditis):
- First choice: Ampicillin monotherapy or ampicillin plus gentamicin for synergy in endocarditis
- Alternative regimen: Ampicillin plus ceftobiprole (emerging option with strong clinical data showing 81% clinical success and 86% microbiological cure) 2, 3
- If beta-lactam intolerant: Linezolid 600 mg IV/PO every 12 hours (strong recommendation) 1
Intra-abdominal Infections:
- Add ampicillin to standard regimens (e.g., ceftriaxone-metronidazole) when enterococcal coverage is needed 4
- For mild-moderate: Ampicillin + gentamicin + metronidazole 4
Uncomplicated Urinary Tract Infections:
- High-dose ampicillin (18-30 g IV daily in divided doses) or amoxicillin 500 mg PO/IV every 8 hours 1
- Alternative: Nitrofurantoin 100 mg PO every 6 hours 1
- Alternative: Fosfomycin 3 g PO single dose 1
For Vancomycin-Resistant E. faecalis (VRE)
Bacteremia/Serious Infections:
- First choice: Linezolid 600 mg IV or PO every 12 hours (strong recommendation, most robust evidence) 1
- Second choice: High-dose daptomycin 8-12 mg/kg/day, or daptomycin combined with beta-lactams (ampicillin, cephalosporins, or carbapenems) 1
Intra-abdominal Infections due to VRE:
- Tigecycline 100 mg IV loading dose, then 50 mg IV every 12 hours 1
Uncomplicated UTI due to VRE:
- Same options as vancomycin-susceptible: high-dose ampicillin/amoxicillin, nitrofurantoin, or fosfomycin 1
Key Clinical Considerations
Resistance Patterns to Monitor
Global surveillance shows E. faecalis maintains relatively low resistance to ampicillin compared to E. faecium, but resistance to chloramphenicol, fosfomycin, imipenem, linezolid, and tetracycline is increasing over time 5. Daptomycin and tigecycline remain highly effective agents 5.
Important Caveats
Genetic lineage matters: Recent genomic data reveals that certain E. faecalis strains (particularly ST6 lineage) show decreased susceptibility to the ampicillin-ceftriaxone combination despite in vitro synergy. For these strains, ampicillin plus daptomycin demonstrates superior growth inhibition and killing 6. This is critical for endocarditis cases where mortality remains high despite standard therapy.
Therapeutic drug monitoring: When using ampicillin-ceftobiprole combinations, TDM should be performed to optimize PK/PD targets (T > 4-8× MIC), particularly with prolonged infusions 2, 3.
Avoid these common pitfalls:
- Do not use vancomycin empirically for E. faecalis—it has intrinsically lower activity than ampicillin for susceptible strains
- Cephalosporins alone (without ampicillin) provide inadequate enterococcal coverage in intra-abdominal infections 4
- For endocarditis, monotherapy is generally insufficient; combination therapy improves outcomes
Duration of Therapy
Treatment duration depends on infection site and clinical response, with endocarditis typically requiring 4-6 weeks and bacteremia 2-4 weeks based on source control 1.